Idorsia Ltd announces that the US Drug Enforcement Administration (DEA) will publish a proposed rule to reclassify dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V… read more.
One in six UK hospital beds is currently occupied by a person with dementia, at a cost to the taxpayer of £2.8 billion annually, with this number set… read more.
Novartis announced that the European Commission (EC) has approved Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with spinal muscular… read more.
Takeda announced that the FDA approved Orzeyful (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.*… read more.
Zevra Therapeutics announced the publication of “Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy” in Molecular Genetics and Metabolism Reports…. read more.
Eisai Co., Ltd. announced that the European Medicines Agency has accepted for evaluation a marketing authorization application for its in-house-discovered and developed orexin receptor antagonist lemborexant for the… read more.
People with dementia, mild cognitive impairment, alcohol addiction, or psychiatric disorders such as schizophrenia show increased brain ageing, each in specific patterns within the brain, according to a… read more.
Emergency Medicine & Intensive Care
Exposure to extreme heat and cold is associated with an increased risk of emergency department (ED) visits among people living with dementia, according to data presented at the… read more.
Zevra Therapeutics announced that the CHMP has adopted a negative opinion regarding the Marketing Authorization Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease type C (NPC),… read more.
Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (brand name: Leqembi IQLIK)… read more.
Takeda China announced that the National Medical Products Administration (NMPA) of China has approved the use of Orzeyful (oveporexton) for the treatment of narcolepsy type 1 (NT1) in… read more.
A hospital’s overall experience with general anesthesia (GA) or conscious sedation (CS) may influence how anesthesia choice affects patient outcomes during mechanical thrombectomy, according to research presented at… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
